174 related articles for article (PubMed ID: 18158768)
61. Magnetically Targeted Nanocapsules for PAA-Cisplatin-Conjugated Cores in PVA/SPIO Shells via Surfactant-Free Emulsion for Reduced Nephrotoxicity and Enhanced Lung Cancer Therapy.
Chiang CS; Tseng YH; Liao BJ; Chen SY
Adv Healthc Mater; 2015 May; 4(7):1066-75. PubMed ID: 25656800
[TBL] [Abstract][Full Text] [Related]
62. The influence of modified pluronic F127 copolymers with higher phase transition temperature on arsenic trioxide-releasing properties and toxicity in a subcutaneous model of rats.
Ma Y; Zhang C; Chen X; Jiang H; Pan S; Easteal AJ; Sun X
AAPS PharmSciTech; 2012 Jun; 13(2):441-7. PubMed ID: 22374430
[TBL] [Abstract][Full Text] [Related]
63. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
64. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
Liu B; Pan S; Dong X; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2006 Jul; 97(7):675-81. PubMed ID: 16827809
[TBL] [Abstract][Full Text] [Related]
65. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
66. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
[TBL] [Abstract][Full Text] [Related]
67. Daunorubicin-loaded magnetic nanoparticles of Fe(3)O(4) greatly enhance the responses of multidrug-resistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy.
Lai BB; Chen BA; Cheng J; Gao F; Xu WL; Ding JH; Gao C; Sun XC; Li GH; Chen WJ; Liu LJ; Li XM; Wang XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):345-51. PubMed ID: 19379564
[TBL] [Abstract][Full Text] [Related]
68. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
69. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
70. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
71. Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Chen G; Wang Y; Huang H; Lin F; Wu D; Sun A; Chang H; Feng Y
Eur J Haematol; 2009 Mar; 82(3):176-83. PubMed ID: 19077051
[TBL] [Abstract][Full Text] [Related]
72. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.
Huang J; Qian W; Wang L; Wu H; Zhou H; Wang AY; Chen H; Yang L; Mao H
Int J Nanomedicine; 2016; 11():3087-99. PubMed ID: 27462153
[TBL] [Abstract][Full Text] [Related]
73. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability.
Kallinteri P; Fatouros D; Klepetsanis P; Antimisiaris SG
J Liposome Res; 2004; 14(1-2):27-38. PubMed ID: 15461930
[TBL] [Abstract][Full Text] [Related]
74. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.
Chen F; Zeng Y; Qi X; Chen Y; Ge Z; Jiang Z; Zhang X; Dong Y; Chen H; Yu Z
Nanomedicine; 2018 Oct; 14(7):2115-2127. PubMed ID: 29898423
[TBL] [Abstract][Full Text] [Related]
75. Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells.
Wang ZY; Song J; Zhang DS
World J Gastroenterol; 2009 Jun; 15(24):2995-3002. PubMed ID: 19554652
[TBL] [Abstract][Full Text] [Related]
76. Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.
Nakata H; Miyazaki T; Iwasaki T; Nakamura A; Kidani T; Sakayama K; Masumoto J; Miura H
Oncol Rep; 2015 Apr; 33(4):1593-8. PubMed ID: 25633802
[TBL] [Abstract][Full Text] [Related]
77. Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.
Zhou H; Wang G; Lu Y; Pan Z
Biomater Sci; 2016 Aug; 4(8):1212-8. PubMed ID: 27315174
[TBL] [Abstract][Full Text] [Related]
78. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors.
Griffin RJ; Lee SH; Rood KL; Stewart MJ; Lyons JC; Lew YS; Park H; Song CW
Neoplasia; 2000; 2(6):555-60. PubMed ID: 11228548
[TBL] [Abstract][Full Text] [Related]
79. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.
Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J
Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348
[TBL] [Abstract][Full Text] [Related]
80. Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.
Sides MD; Sosulski ML; Luo F; Lin Z; Flemington EK; Lasky JA
Virol J; 2013 May; 10():152. PubMed ID: 23680002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
